Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DGAT1 | O75907 | 4/20 | 0.43 |
| ▸ | GPR119 | Q8TDV5 | 4/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.42 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.39 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.37 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.37 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.36 |
| ▸ | CHRNA7 | P36544 | 1/20 | 0.36 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL601775 | 1.00 | DGAT1 (0.43) | DGAT1GPR119RAB9AHRH3PDE4B | |
| SCHEMBL602562 | 0.86 | MAPT (0.48) | DGAT1GPR119MAPT | |
| SCHEMBL602561 | 0.86 | MAPT (0.48) | DGAT1GPR119MAPT | |
| SCHEMBL3346693 | 0.84 | GPR119 (0.62) | GPR119HRH3PDE4BMAPTALDH1A1 | |
| SCHEMBL796305 | 0.80 | PDE4B (0.46) | RAB9AHRH3PDE4BMAPTALDH1A1 | |
| SCHEMBL1588694 | 0.80 | GPR119 (0.46) | DGAT1GPR119RAB9AHRH3 | |
| SCHEMBL5532726 | 0.80 | DGAT1 (0.60) | DGAT1GPR119HRH3EPHX2 | |
| SCHEMBL15152753 | 0.80 | DGAT1 (0.47) | DGAT1GPR119 | |
| SCHEMBL15152756 | 0.80 | DGAT1 (0.47) | DGAT1GPR119 | |
| SCHEMBL13769570 | 0.80 | DGAT1 (0.60) | DGAT1GPR119HRH3EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8546391-B2 | Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-8546391-B2 | Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-8546391-B2 | Thiadiazole and oxadiazole derivatives, preparation thereof and therapeutic use thereof | SANOFI (FR) | 2013-10-01 | — | — | US | disclosed |
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-16 | — | — | US | disclosed |
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-16 | — | — | US | disclosed |
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | SANOFI (FR) | 2012-02-16 | — | — | US | disclosed |
| WO-2010086551-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF, AND THERAPEUTIC USE THEREOF | SANOFI-AVENTIS (FR) | 2010-08-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040984-A1 | THIADIAZOLE AND OXADIAZOLE DERIVATIVES, PREPARATION THEREOF AND THERAPEUTIC USE THEREOF | OXA1L, CYP11B2, CYP11B1 | DGAT1 3495/4885GPR119 3905/4885RAB9A 3120/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.